Argenx SE Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease CI Oct. 08 Argenx SE Discontinues Phase 3 Unity Study of Efgartigimod Sc in Sjögren's Disease CI Oct. 08 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results